Proteome-based insights for IDH-mutant glioma classification

Severina Leu; Gregor Hutter; Jean-Louis Boulay

doi:10.1016/j.xcrm.2022.100909

Proteome-based insights for IDH-mutant glioma classification

Cell Rep Med. 2023 Jan 17;4(1):100909. doi: 10.1016/j.xcrm.2022.100909.

Authors

Severina Leu¹, Gregor Hutter¹, Jean-Louis Boulay²

Affiliations

¹ Department of Neurosurgery and Laboratory of Brain Tumor Immunotherapy and Biology, Department of BioMedicine, University Hospital Basel and University of Basel, Hebelstrasse 20, 4031 Basel, Switzerland.
² Department of Neurosurgery and Laboratory of Brain Tumor Immunotherapy and Biology, Department of BioMedicine, University Hospital Basel and University of Basel, Hebelstrasse 20, 4031 Basel, Switzerland. Electronic address: jean-louis.boulay@unibas.ch.

Abstract

In this issue, Bader et al.¹ characterize the proteomes of diffuse glioma brain tumors by liquid chromatography mass spectrometry and classify isocitrate dehydrogenase (IDH)-mutant gliomas into two subtypes, which differ in oncogenic pathways and aerobic/anaerobic energy metabolism.

Publication types

Comment

MeSH terms

Brain Neoplasms* / genetics
Glioma* / genetics
Glioma* / pathology
Humans
Isocitrate Dehydrogenase / genetics
Mutation
Proteome / genetics

Substances

Isocitrate Dehydrogenase
Proteome